tradingkey.logo
tradingkey.logo
検索

ANI Pharmaceuticals Inc

ANIP
ウォッチリストに追加
78.010USD
-1.570-1.97%
終値 05/15, 16:00ET15分遅れの株価
1.77B時価総額
18.96直近12ヶ月PER

ANI Pharmaceuticals Inc

78.010
-1.570-1.97%

詳細情報 ANI Pharmaceuticals Inc 企業名

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.

ANI Pharmaceuticals Incの企業情報

企業コードANIP
会社名ANI Pharmaceuticals Inc
上場日May 04, 2000
最高経営責任者「CEO」Lalwani (Nikhil Suresh)
従業員数897
証券種類Ordinary Share
決算期末May 04
本社所在地210 Main Street West
都市BAUDETTE
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号56623
電話番号12186343500
ウェブサイトhttps://www.anipharmaceuticals.com/
企業コードANIP
上場日May 04, 2000
最高経営責任者「CEO」Lalwani (Nikhil Suresh)

ANI Pharmaceuticals Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
311.43K
+0.42%
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
290.27K
-45.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
82.54K
-22.14%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
61.18K
-41.94%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
52.41K
-11.45%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
51.95K
-12.65%
Mr. Thomas Andrew (Thom) Rowland
Mr. Thomas Andrew (Thom) Rowland
Senior Vice President, Head of Established Brands
Senior Vice President, Head of Established Brands
37.85K
-12.61%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
36.52K
--
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
25.16K
--
Mr. Matthew J. (Matt) Leonard
Mr. Matthew J. (Matt) Leonard
Independent Director
Independent Director
6.86K
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
311.43K
+0.42%
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
290.27K
-45.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
82.54K
-22.14%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
61.18K
-41.94%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
52.41K
-11.45%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
51.95K
-12.65%

収益内訳

通貨: USD更新時刻: Mon, Apr 6
通貨: USD更新時刻: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
事業別USD
会社名
収益
比率
Sales of generic pharmaceutical products
384.11M
43.48%
Sales of rare disease pharmaceutical products
347.78M
39.37%
Sales of Cortrophin Gel
347.78M
39.37%
Sales of branded pharmaceutical products
76.61M
8.67%
地域別USD
会社名
収益
比率
United States
852.44M
96.50%
International
30.92M
3.50%
事業別
地域別
事業別USD
会社名
収益
比率
Sales of generic pharmaceutical products
384.11M
43.48%
Sales of rare disease pharmaceutical products
347.78M
39.37%
Sales of Cortrophin Gel
347.78M
39.37%
Sales of branded pharmaceutical products
76.61M
8.67%

株主

更新時刻: Sun, May 10
更新時刻: Sun, May 10
株主統計
種類
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
10.76%
Meridian Venture Partners
4.46%
Vanguard Capital Management, LLC
3.62%
State Street Investment Management (US)
3.20%
Millennium Management LLC
2.37%
他の
75.58%
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
10.76%
Meridian Venture Partners
4.46%
Vanguard Capital Management, LLC
3.62%
State Street Investment Management (US)
3.20%
Millennium Management LLC
2.37%
他の
75.58%
種類
株主統計
比率
Investment Advisor
42.89%
Investment Advisor/Hedge Fund
23.64%
Hedge Fund
20.43%
Research Firm
6.41%
Individual Investor
5.68%
Private Equity
4.46%
Pension Fund
2.51%
Corporation
1.92%
Bank and Trust
1.50%

機関投資家保有株

更新時刻: Wed, Apr 1
更新時刻: Wed, Apr 1
報告期間
機関投資家数
保有株式数
比率
変動額
2026Q1
555
23.15M
101.74%
+57.73K
2025Q4
507
21.97M
100.49%
+14.84K
2025Q3
525
21.96M
103.27%
+407.79K
2025Q2
506
21.46M
110.44%
-446.10K
2025Q1
489
21.61M
106.49%
-1.37M
2024Q4
469
21.12M
108.93%
+156.97K
2024Q3
453
20.75M
88.54%
+3.60M
2024Q2
425
17.36M
85.19%
+1.07M
2024Q1
403
16.22M
82.13%
-1.01M
2023Q4
390
16.10M
82.95%
+39.70K
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
BlackRock Institutional Trust Company, N.A.
2.45M
10.91%
+103.61K
+4.42%
Dec 31, 2025
Meridian Venture Partners
1.01M
4.53%
-150.00K
-12.88%
Aug 21, 2025
State Street Investment Management (US)
727.20K
3.24%
+15.50K
+2.18%
Dec 31, 2025
Millennium Management LLC
539.66K
2.41%
+474.42K
+727.14%
Dec 31, 2025
Dimensional Fund Advisors, L.P.
487.67K
2.18%
-17.76K
-3.51%
Dec 31, 2025
Soleus Capital Management, L.P.
486.24K
2.17%
+146.00K
+42.91%
Dec 31, 2025
Tang Capital Management, LLC
481.44K
2.15%
+163.94K
+51.63%
Dec 31, 2025
Deep Track Capital LP
477.68K
2.13%
+27.68K
+6.15%
Dec 31, 2025
詳細を見る

関連ETF

更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Invesco Pharmaceuticals ETF
2.63%
State Street SPDR S&P Pharmaceuticals ETF
2.42%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.95%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.63%
Innovator IBD Breakout Opportunities ETF
1.38%
Innovator IBD 50 Fund ETF
1.02%
Invesco Dorsey Wright Healthcare Momentum ETF
0.98%
Invesco S&P SmallCap Health Care ETF
0.96%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.92%
First Trust Small Cap Growth AlphaDEX Fund
0.67%
詳細を見る
Invesco Pharmaceuticals ETF
比率2.63%
State Street SPDR S&P Pharmaceuticals ETF
比率2.42%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
比率1.95%
Pacer US Small Cap Cash Cows Growth Leaders ETF
比率1.63%
Innovator IBD Breakout Opportunities ETF
比率1.38%
Innovator IBD 50 Fund ETF
比率1.02%
Invesco Dorsey Wright Healthcare Momentum ETF
比率0.98%
Invesco S&P SmallCap Health Care ETF
比率0.96%
Janus Henderson Small/Mid Cap Growth Alpha ETF
比率0.92%
First Trust Small Cap Growth AlphaDEX Fund
比率0.67%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
KeyAI